Last year, PILMA in collaboration with union health care and benefits expert Randy DeFrehn released a report titled “An Understanding and Implications of the Cost Drivers in the Drug Supply Chain.” PILMA combined DeFrehn’s findings with data from a new report by Berkeley Research Group to extrapolate on the original report and provide insight into which entities in the supply chain are receiving an increasing share of revenue from prescription medicines.
The Pharmaceutical Industry Labor-Management Association (PILMA) and the California Biopharmaceutical Industry Labor-Management Association (CBPILMA) hosted an event at the Democratic Governors Association’s conference in Beverly Hills highlighting how investing in high skilled labor supports 21st century pharmaceutical innovation.
The partnership between the biopharmaceutical industry and labor unions fosters a collaborative environment that keeps each side innovating. Training programs equip union workers with the skills to build and maintain state-of-the-art facilities providing industry with the capability to discover life-saving cures.
The AFL-CIO Blog highlights the value of the PILMA coalition: “One staple of PILMA’s program—along with conferences and other get-togethers—is to provide tours of union training facilities, which allow industry officials to see firsthand the skill levels and training union workers bring to the specialized construction needs of the biotechnology industry.” Read the Full Article